BOSTON, United States and ROLLE, Switzerland, April 23, 2024 — SOPHiA GENETICS, a...
SOPHiA GENETICS to Announce Financial Results for First Quarter 2024 on May 7, 2024
read more
Press releases
SOPHiA GENETICS Announces Syndicate Bio as First Liquid Biopsy Customer in Africa
Syndicate Bio to implement new liquid biopsy offering to advance cancer diagnostics throughout...
SOPHiA GENETICS Announces Unilabs is using its AI Technology to Detect Homologous Recombination Deficiency (HRD)
European-based Unilabs has deployed the SOPHiA DDM™ Platform across its network in Switzerland to...
Laboratorio Barnafi-Krause is Live on SOPHiA DDM™
The Chile-based Laboratory is using SOPHiA GENETICS’ platform to advance its research capabilities...
SOPHiA GENETICS and Strand Life Sciences Announce New Strategic Partnership
The companies will join forces to advance the use of precision medicine on a global scale ...
SOPHiA GENETICS Announces First Homologous Recombination Deficiency (HRD) Customer in Canada
University of Saskatchewan’s (USask) Advanced Diagnostics Research Laboratory will use SOPHiA DDM™...
SOPHiA GENETICS and The French Kidney Cancer Research Network (UroCCR) Publish Results from Multiyear Collaboration
New Multimodal Algorithm Highlights Predictive Benefit Of Artificial Intelligence (AI) for Cancer...
SOPHiA GENETICS Announces New Customer in Costa Rica
Universidad de Costa Rica is live on SOPHiA GENETICS’ technology Boston, MA and Rolle,...
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2023 Results
Strong momentum to continue in 2024 as SOPHiA GENETICS announces record revenue, 35 new customer...
SOPHiA GENETICS to Participate in Fireside Chat at the 44th Annual TD Cowen Health Care Conference
SOPHiA GENETICS to Participate in Fireside Chat at the 44th Annual TD Cowen Health Care Conference...
SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full-Year 2023 on March 5, 2024
BOSTON, United States and ROLLE, Switzerland, February 20, 2024 — SOPHiA GENETICS (Nasdaq:...
SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain
SOPHiA GENETICS and AstraZeneca Spain expand HRD testing program to support molecular diagnosis of...